000 02796nam a22003735i 4500
001 309808
003 MX-SnUAN
005 20160429160325.0
007 cr nn 008mamaa
008 150903s2008 sz | o |||| 0|eng d
020 _a9783764374259
_99783764374259
024 7 _a10.1007/9783764374259
_2doi
035 _avtls000362753
039 9 _a201509031039
_bVLOAD
_c201405070334
_dVLOAD
_y201402211057
_zstaff
040 _aMX-SnUAN
_bspa
_cMX-SnUAN
_erda
050 4 _aRM1-950
100 1 _aWilding, John P. H.
_eeditor.
_9350269
245 1 0 _aPharmacotherapy of Obesity /
_cedited by John P. H. Wilding.
264 1 _aBasel :
_bBirkhäuser Basel,
_c2008.
300 _brecurso en línea.
336 _atexto
_btxt
_2rdacontent
337 _acomputadora
_bc
_2rdamedia
338 _arecurso en línea
_bcr
_2rdacarrier
347 _aarchivo de texto
_bPDF
_2rda
490 0 _aMilestones in Drug Therapy
500 _aSpringer eBooks
505 0 _aWhy drugs? -- Some historical aspects of drug treatment for obesity -- Regulation of energy balance — towards rational drug design in obesity -- Intestinal lipase inhibitors -- Sibutramine -- The endocannabinoid system as a target for obesity treatment -- Using the body’s natural signals — gut hormones -- Influencing energy expenditure and substrate utilisation.
520 _aObesity has become a major epidemic that now rivals smoking as a risk to public health. The ensuing epidemics of diabetes, vascular disease and other complications are set to overwhelm the healthcare systems of wealthy and poorer nations alike. The need for effective pharmacotherapy has never been greater. This book takes a new look at the many potential targets for drug development for regulation of body weight, placing them in the context of the chequered history of drug development for obesity and currently available therapies. Potential peripheral and central nervous system targets are discussed in detail by authors with extensive knowledge and research experience in the science of body weight regulation, and its translation into effective therapies that will benefit patients. This book is of interest to clinicians, researchers in the field and members of the pharmaceutical industry who are interested in learning more about the current state of the art and future directions in the pharmacotherapy of obesity.
590 _aPara consulta fuera de la UANL se requiere clave de acceso remoto.
710 2 _aSpringerLink (Servicio en línea)
_9299170
776 0 8 _iEdición impresa:
_z9783764371388
856 4 0 _uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/978-3-7643-7425-9
_zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942 _c14
999 _c309808
_d309808